ArticleEMBO molecular medicine2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Engineered tissues and strategies to overcome challenges in drug development.Advanced drug delivery reviews · 2020Pooled it
- Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma.Cell death & disease · 2026Article
- Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors.Pharmaceutics · 2025Article
- Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib).Cell communication and signaling : CCS · 2024Article
- Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma, Quantitative Analysis, Optical Clearing, and Mathematical Modeling.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- The EDN1/EDNRA/β‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation.International journal of oncology · 2023Article
- New Insights into the Phenotype Switching of Melanoma.Cancers · 2022Review
- Melanoma stimulates the proteolytic activity of HaCaT keratinocytes.Cell communication and signaling : CCS · 2022Article
- Multi-modal molecular programs regulate melanoma cell state.Nature communications · 2022Article
- Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.Cancer gene therapy · 2022Article
- Review
- Review
- The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance.Frontiers in molecular biosciences · 2022Review
- Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis.Cancers · 2021Review
- Arena3Dweb: interactive 3D visualization of multilayered networks.Nucleic acids research · 2021Article
- Participation of keratinocyte- and fibroblast-derived factors in melanocyte homeostasis, the response to UV, and pigmentary disorders.Pigment cell & melanoma research · 2021Review
- How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.International journal of molecular sciences · 2021Review
- Many Distinct Ways Lead to Drug Resistance inLife (Basel, Switzerland) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 7 institutions in 6 countries.
Michael P SmithManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Emily J RowlingManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Zsofia MiskolcziManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Jennifer FergusonManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Loredana SpoerriTranslational Research Institute, The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia.
Nikolas K HaassTranslational Research Institute, The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Qld, Australia.
Olivia SlossManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Sophie McEntegartManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Imanol ArozarenaManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Alex von KriegsheimSystems Biology Ireland, School of Medicine, UCD, Dublin 4, Ireland.
Javier RodriguezSystems Biology Ireland, School of Medicine, UCD, Dublin 4, Ireland.
Holly BruntonManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Jivko KmarashevDepartment of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland.
Mitchell P LevesqueDepartment of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland.
Reinhard DummerDepartment of Dermatology, Universitätsspital Zürich, University of Zurich, Zurich, Switzerland.
Dennie T FrederickDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Miles C AndrewsDivision of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zachary A CooperDivision of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith T FlahertyDepartment of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Jennifer A WargoDivision of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Claudia WellbrockManchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK claudia.wellbrock@manchester.ac.uk.ORCID 0000-0002-3825-6381
University of Manchester · GBThe University of Texas MD Anderson Cancer Center · USUniversity of Zurich · CHMassachusetts General Hospital · USUniversity College Dublin · IEThe University of Sydney · AUTranslational Research Institute · AU
Funding
Role of Tumor Stroma in Therapeutic Response and ResistanceU54CA163125 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHIN, LYNDA, FLAHERTY, KEITH T · 2011 to 2015
$4.4MExploring synergy of combined BRAF-targeted therapy & immunotherapy for melanomaK08CA160692 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2012 to 2016
$713kCancer Research UK 16416Cancer Research UK C11591/A16416Medical Research Council MR/L011840/1NCI NIH HHS K08 CA160692NCI NIH HHS U54 CA163125Wellcome TrustWellcome Trust R116433
Abstract
Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a "MITF-high" phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulations of the
Indexed as
AnimalsAntineoplastic AgentsBosentanCell Line, TumorDisease Models, AnimalEndothelin Receptor AntagonistsHeterograftsHumansMelanomaMice, NudeNeoplasm TransplantationProto-Oncogene Proteins B-rafSulfonamidesTreatment OutcomeZebrafishAntineoplastic AgentsBosentanBRAF protein, humanEndothelin Receptor AntagonistsProto-Oncogene Proteins B-rafSulfonamidesAXLBRAFendothelinmelanomaMITF
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.